COVID-19 Anosmia Study

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To capture the natural history of COVID-19 associated olfactory dysfunction as measured by two patient reported outcome measures (SNOT-22, QOD-NS) and a 6-week BSIT with a comparison to an intervention arm receiving daily omega-3 supplements.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Icahn School of Medicine at Mount Sinai

Criteria

Inclusion Criteria:

• Adults (18 years of age or older) with self-reported new-onset olfactory dysfunction

• Positive COVID-19 diagnosis will be deemed eligible for inclusion.

Exclusion Criteria:

• Patients <18 years of age

• Patients who are unable to provide informed consent

• Patients without a positive COVID-19 PCR result obtained through nasopharyngeal swab - Patients with a COVID-19 diagnosis but without self-reported anosmia

• Patients with severe COVID-19 disease as defined by the Mouth Sinai Health System Treatment Guidelines for SARS-COV-2 (requiring high flow nasal cannula, non-rebreather, CPAP/BIPAP, or mechanical ventilation OR patients requiring pressor medication OR patients with evidence of end organ damage)

• Patients with pre-existing self-reported olfactory dysfunction

• Patients with a history of chronic nasal/sinus infections (rhinosinusitis) or history of endoscopic sinus surgery

• Patients using nasal steroid sprays or irrigations for any reason

• Patients who are prisoners of the state

• Patients who have psychiatric or developmental disorder conditions that may impair ability to provide informed consent

• Patients will also be excluded if they have an allergy to fish or an omega-3 supplement, or do not eat fish or fish- containing substances for any reason